What I have: 4 mg · retatrutide.
I suspect the usual explanation for this is wrong, or at least incomplete.
I am aware this may have a boring answer. I would still like the boring answer stated clearly.
What is actually going on here, physically?
Two administrations of 2 mg instead of one of 4 mg — the same 4 mg a week either way. Total weekly exposure is unchanged; what changes is the peak-to-trough ratio, and for an agent with a half-life measured in days the trough barely moves because the dosing interval is already short relative to it. The arithmetic is the easy part: 4 ÷ 2 = 2. Whether it is worth doing is a pharmacokinetic question, and nothing here is medical advice.
The short version: pharmacokinetically defensible for shorter half-lives, close to pointless for the weekly agents, and it multiplies handling opportunities either way.
Reported tolerability improvements with splitting may reflect the smaller absolute amount arriving at once rather than the exposure profile, which is a different mechanism and is not well characterised.
| Vial | Diluent | Concentration | 0.25 mg | 0.5 mg | 1 mg | 2.5 mg |
|---|---|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 5 u | 10 u | 20 u | 50 u |
| 5 mg | 2 mL | 2.5 mg/mL | 10 u | 20 u | 40 u | 100 u |
| 10 mg | 1 mL | 10 mg/mL | 2.5 u | 5 u | 10 u | 25 u |
| 10 mg | 2 mL | 5 mg/mL | 5 u | 10 u | 20 u | 50 u |
| 10 mg | 3 mL | 3.33 mg/mL | 7.5 u | 15 u | 30 u | 75 u |
Units are U-100 insulin units, where 1 unit = 0.01 mL. Divide dose by concentration for millilitres, then multiply by 100.
For a thirteen-hour half-life agent dosed daily, τ/t½ is about 1.8 and the swing is nearly fourfold, which is why the daily agents feel peakier and why splitting them would have more effect.
The peak-to-trough relationship 2^(τ/t½) is standard pharmacokinetics for a one-compartment model with first-order elimination and is the correct tool for this question.
More injections means more handling risk, and that cost is certain while the benefit is not.
If you cannot read half the dose accurately, you cannot split it accurately.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsOn the detail: the relevant arithmetic is the accumulation ratio, which tells you how flat the profile already is at the current interval.
Halving a dose accurately requires the reading resolution to support it. A 10-unit dose split into two 5-unit doses is at the coarse end of any barrel.
Concretely, each additional injection is an additional stopper entry, an additional needle and an additional opportunity to introduce contamination into a preparation that has no release testing behind it.
Titration schedules in the trial programmes were designed to manage gastrointestinal tolerability and are the evidenced approach to that problem.
Halving a dose you cannot read accurately introduces an error larger than the effect you are chasing.
Slower titration has evidence; splitting has anecdote. Prefer the first.
edited 14 Oct 2024 by marta_okonkwo — reworded for clarity after a comment
Answer first: splitting a weekly dose into smaller more frequent doses reduces peak-to-trough variation, and whether that helps depends entirely on the half-life of the agent.
A slower titration achieves a lower peak exposure with fewer handling steps, which is why it is the better-evidenced answer to the same problem.
On the detail: accumulation to steady state takes four to five half-lives regardless of how the dose is divided. Splitting does not shorten it and does not change the average exposure.
The caveat is that no split schedule has been evaluated in a trial, so the whole discussion is inference plus report.
For a weekly half-life, weekly dosing is already flat. Splitting buys very little.
edited 14 Oct 2024 by tenth_of_a_unit — added the method parameters
If the goal is tolerability, a slower titration has better evidence behind it than a split schedule.
For a drug with elimination half-life t½ dosed at interval τ, the peak-to-trough ratio at steady state is 2^(τ/t½). With a one-week half-life dosed weekly, τ/t½ = 1, so the ratio is 2 — a factor of two between peak and trough, which is already flat by pharmacological standards.
Every split is another stopper entry. Count that cost.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.